Pharmacological treatment options for osteoarthritis: focus on symptomatic slow-acting drugs for osteoarthritis (SYSADOA) and individual patient characteristics: Resolution of the International Expert Meeting
The paper presents the results of the Osteoarthritis (OA) Expert Council held on September 8, 2019, which was attended by Russian and foreign specialists. The experts considered pharmacological treatment options for OA. The expert meeting resolution states that the treatment of patients with OA shou...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2019-10-01
|
| Series: | Современная ревматология |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/973 |
| _version_ | 1797876692874690560 |
|---|---|
| author | A. M. Lila L. I. Alekseeva A. R. Babaeva I. Z. Gaydukova G. Gandolini E. V. Zonova R. Capelli A. E. Karateev S. S. Kopenkin N. A. Martusevich O. B. Nesmeyanova E. N. Otteva F. Rannuе T. A. Raskina M. L. Sukhareva E. A. Taskina N. V. Chichasova S. P. Yakupova |
| author_facet | A. M. Lila L. I. Alekseeva A. R. Babaeva I. Z. Gaydukova G. Gandolini E. V. Zonova R. Capelli A. E. Karateev S. S. Kopenkin N. A. Martusevich O. B. Nesmeyanova E. N. Otteva F. Rannuе T. A. Raskina M. L. Sukhareva E. A. Taskina N. V. Chichasova S. P. Yakupova |
| author_sort | A. M. Lila |
| collection | DOAJ |
| description | The paper presents the results of the Osteoarthritis (OA) Expert Council held on September 8, 2019, which was attended by Russian and foreign specialists. The experts considered pharmacological treatment options for OA. The expert meeting resolution states that the treatment of patients with OA should be based on an individual assessment of the patient and on a modern evidence base of therapy efficacy.Treatment of patients with OA is based on the principles of evidence-based medicine that requires an integrated approach and the need of SYSADOAs prescription. Combined drugs with therapeutic dosages of chondroitin sulfate and glucosamine in the early stages of the disease are available as basic agents. The place of paracetamol in the anesthetic therapy algorithm in OA needs to be clarified. It is also noted that when choosing nonsteroidal anti-inflammatory drugs for OA treatment, it is important to take into account individual patient characteristics and the presence of comorbidities. |
| first_indexed | 2024-04-10T02:06:40Z |
| format | Article |
| id | doaj.art-afb912444e9f44eabd7c491850753f20 |
| institution | Directory Open Access Journal |
| issn | 1996-7012 2310-158X |
| language | Russian |
| last_indexed | 2024-04-10T02:06:40Z |
| publishDate | 2019-10-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj.art-afb912444e9f44eabd7c491850753f202023-03-13T08:39:27ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2019-10-0113414314710.14412/1996-7012-2019-4-143-1472225Pharmacological treatment options for osteoarthritis: focus on symptomatic slow-acting drugs for osteoarthritis (SYSADOA) and individual patient characteristics: Resolution of the International Expert MeetingA. M. Lila0L. I. Alekseeva1A. R. Babaeva2I. Z. Gaydukova3G. Gandolini4E. V. Zonova5R. Capelli6A. E. Karateev7S. S. Kopenkin8N. A. Martusevich9O. B. Nesmeyanova10E. N. Otteva11F. Rannuе12T. A. Raskina13M. L. Sukhareva14E. A. Taskina15N. V. Chichasova16S. P. Yakupova17ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»ФГБОУ ВО «Волгоградский государственный медицинский университет» Минздрава РоссииФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава Россииклиника Irccs S.M. Nascente-Fond. Don C. GnocchiФГБОУ ВО «Новосибирский государственный медицинский университет» Минздрава РоссииГоспиталь Fatebenefratelli E Oftalmico-MilanoФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава РоссииБелорусский государственный медицинский УниверситетГБУЗ «Челябинская областная клиническая больница»КГБОУ ДПО «Институт повышения квалификации специалистов здравоохранения» Минздрава Хабаровского края; КГБУЗ «Краевая клиническая больница №1 им. профессора С.И. Сергеева»Институт ревматологии Cochin Hospital, AP-HPФГБОУ ВО «Кемеровский государственный медицинский университет» Минздрава РоссииФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»ФГБОУ ВО «Казанский государственный медицинский университет» Минздрава РоссииThe paper presents the results of the Osteoarthritis (OA) Expert Council held on September 8, 2019, which was attended by Russian and foreign specialists. The experts considered pharmacological treatment options for OA. The expert meeting resolution states that the treatment of patients with OA should be based on an individual assessment of the patient and on a modern evidence base of therapy efficacy.Treatment of patients with OA is based on the principles of evidence-based medicine that requires an integrated approach and the need of SYSADOAs prescription. Combined drugs with therapeutic dosages of chondroitin sulfate and glucosamine in the early stages of the disease are available as basic agents. The place of paracetamol in the anesthetic therapy algorithm in OA needs to be clarified. It is also noted that when choosing nonsteroidal anti-inflammatory drugs for OA treatment, it is important to take into account individual patient characteristics and the presence of comorbidities.https://mrj.ima-press.net/mrj/article/view/973 |
| spellingShingle | A. M. Lila L. I. Alekseeva A. R. Babaeva I. Z. Gaydukova G. Gandolini E. V. Zonova R. Capelli A. E. Karateev S. S. Kopenkin N. A. Martusevich O. B. Nesmeyanova E. N. Otteva F. Rannuе T. A. Raskina M. L. Sukhareva E. A. Taskina N. V. Chichasova S. P. Yakupova Pharmacological treatment options for osteoarthritis: focus on symptomatic slow-acting drugs for osteoarthritis (SYSADOA) and individual patient characteristics: Resolution of the International Expert Meeting Современная ревматология |
| title | Pharmacological treatment options for osteoarthritis: focus on symptomatic slow-acting drugs for osteoarthritis (SYSADOA) and individual patient characteristics: Resolution of the International Expert Meeting |
| title_full | Pharmacological treatment options for osteoarthritis: focus on symptomatic slow-acting drugs for osteoarthritis (SYSADOA) and individual patient characteristics: Resolution of the International Expert Meeting |
| title_fullStr | Pharmacological treatment options for osteoarthritis: focus on symptomatic slow-acting drugs for osteoarthritis (SYSADOA) and individual patient characteristics: Resolution of the International Expert Meeting |
| title_full_unstemmed | Pharmacological treatment options for osteoarthritis: focus on symptomatic slow-acting drugs for osteoarthritis (SYSADOA) and individual patient characteristics: Resolution of the International Expert Meeting |
| title_short | Pharmacological treatment options for osteoarthritis: focus on symptomatic slow-acting drugs for osteoarthritis (SYSADOA) and individual patient characteristics: Resolution of the International Expert Meeting |
| title_sort | pharmacological treatment options for osteoarthritis focus on symptomatic slow acting drugs for osteoarthritis sysadoa and individual patient characteristics resolution of the international expert meeting |
| url | https://mrj.ima-press.net/mrj/article/view/973 |
| work_keys_str_mv | AT amlila pharmacologicaltreatmentoptionsforosteoarthritisfocusonsymptomaticslowactingdrugsforosteoarthritissysadoaandindividualpatientcharacteristicsresolutionoftheinternationalexpertmeeting AT lialekseeva pharmacologicaltreatmentoptionsforosteoarthritisfocusonsymptomaticslowactingdrugsforosteoarthritissysadoaandindividualpatientcharacteristicsresolutionoftheinternationalexpertmeeting AT arbabaeva pharmacologicaltreatmentoptionsforosteoarthritisfocusonsymptomaticslowactingdrugsforosteoarthritissysadoaandindividualpatientcharacteristicsresolutionoftheinternationalexpertmeeting AT izgaydukova pharmacologicaltreatmentoptionsforosteoarthritisfocusonsymptomaticslowactingdrugsforosteoarthritissysadoaandindividualpatientcharacteristicsresolutionoftheinternationalexpertmeeting AT ggandolini pharmacologicaltreatmentoptionsforosteoarthritisfocusonsymptomaticslowactingdrugsforosteoarthritissysadoaandindividualpatientcharacteristicsresolutionoftheinternationalexpertmeeting AT evzonova pharmacologicaltreatmentoptionsforosteoarthritisfocusonsymptomaticslowactingdrugsforosteoarthritissysadoaandindividualpatientcharacteristicsresolutionoftheinternationalexpertmeeting AT rcapelli pharmacologicaltreatmentoptionsforosteoarthritisfocusonsymptomaticslowactingdrugsforosteoarthritissysadoaandindividualpatientcharacteristicsresolutionoftheinternationalexpertmeeting AT aekarateev pharmacologicaltreatmentoptionsforosteoarthritisfocusonsymptomaticslowactingdrugsforosteoarthritissysadoaandindividualpatientcharacteristicsresolutionoftheinternationalexpertmeeting AT sskopenkin pharmacologicaltreatmentoptionsforosteoarthritisfocusonsymptomaticslowactingdrugsforosteoarthritissysadoaandindividualpatientcharacteristicsresolutionoftheinternationalexpertmeeting AT namartusevich pharmacologicaltreatmentoptionsforosteoarthritisfocusonsymptomaticslowactingdrugsforosteoarthritissysadoaandindividualpatientcharacteristicsresolutionoftheinternationalexpertmeeting AT obnesmeyanova pharmacologicaltreatmentoptionsforosteoarthritisfocusonsymptomaticslowactingdrugsforosteoarthritissysadoaandindividualpatientcharacteristicsresolutionoftheinternationalexpertmeeting AT enotteva pharmacologicaltreatmentoptionsforosteoarthritisfocusonsymptomaticslowactingdrugsforosteoarthritissysadoaandindividualpatientcharacteristicsresolutionoftheinternationalexpertmeeting AT frannue pharmacologicaltreatmentoptionsforosteoarthritisfocusonsymptomaticslowactingdrugsforosteoarthritissysadoaandindividualpatientcharacteristicsresolutionoftheinternationalexpertmeeting AT taraskina pharmacologicaltreatmentoptionsforosteoarthritisfocusonsymptomaticslowactingdrugsforosteoarthritissysadoaandindividualpatientcharacteristicsresolutionoftheinternationalexpertmeeting AT mlsukhareva pharmacologicaltreatmentoptionsforosteoarthritisfocusonsymptomaticslowactingdrugsforosteoarthritissysadoaandindividualpatientcharacteristicsresolutionoftheinternationalexpertmeeting AT eataskina pharmacologicaltreatmentoptionsforosteoarthritisfocusonsymptomaticslowactingdrugsforosteoarthritissysadoaandindividualpatientcharacteristicsresolutionoftheinternationalexpertmeeting AT nvchichasova pharmacologicaltreatmentoptionsforosteoarthritisfocusonsymptomaticslowactingdrugsforosteoarthritissysadoaandindividualpatientcharacteristicsresolutionoftheinternationalexpertmeeting AT spyakupova pharmacologicaltreatmentoptionsforosteoarthritisfocusonsymptomaticslowactingdrugsforosteoarthritissysadoaandindividualpatientcharacteristicsresolutionoftheinternationalexpertmeeting |